에 대한 최신 뉴스 Biohaven (NYSE:BHVN) 주식

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

The Archer Aviation Trade

Mid Cap

News

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRPT

SRRK

URBN

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아처 에비에이션(NYSE:ACHR) 주식은 지난주 65.57% 급등했다.

아처 및 어번 아웃피터스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (11월 25일-29일)

nike shutter2

Earnings

Long Ideas

Pre-Market Outlook

Markets

TRAK

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 어큐이티 브랜즈(NYSE:AYI)가 분기별 실적을 주당 $4.28, 매출 $10.2억 달러로 예상하고 있으며, 시장 개장 전에 실적을 발표할 것이라고 전했다. 어큐이티 브랜즈의 주식은 애프터 마켓에서 1.7% 상승하여 $279.94에 거래되었다.

화요일 주목해야 할 주식: 어큐이티 브랜즈, 나이키, 리포시트랙 그리고 2종목

weight loss ai

Biotech

Equities

Health Care

Global

GPCR

RHHBY

스트럭처 테라퓨틱스(NASDAQ:GPCR)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다. What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#34;비중확대(Overweight)&#34; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.

스트럭처 테라퓨틱스 주식은 비만 치료제 시장의 돌파구로 80% 상승 예상: JP모건

Biohaven Ltd

<a href="https://www.scmp.com/news/china/science/article/3315999/china-has-begun-issuing-rare-earth-export-licenses-european-firms-eu-sources-say">https://www.scmp.com/news/china/science/article/3315999/china-has-begun-issuing-rare-earth-export-licenses-european-firms-eu-sources-say</a>

General

Market Vectors Rare Earth/Strategic Metals Etf

REMX

' China has begun issuing rare earth export licenses to European firms, EU sources say'- South China Morning Post

BMO Capital analyst Etienne Ricard maintains Sprott (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SII#TSX">SII</a>) with a Outperform and raises the price target from C$80 to C$94.

Price Target

Analyst Ratings

TSX:SII

BMO Capital Maintains Outperform on Sprott, Raises Price Target to C$94

Shares of Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) are up Thursday following a report suggesting CoreWeave inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) is in discussions to acquire the <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46102704/coreweave-stock-is-moving-lower-wednesday-whats-going-on">bitcoin mining and hosting company.</a>
What To Know: According to<a href="https://www.wsj.com/business/deals/coreweave-in-talks-to-buy-core-scientific-ed821c09"> the Wall Street Journal</a>, the two companies are in talks and could finalize a deal in the coming weeks if talks proceed without issue. CoreWeave previously made an unsuccessful attempt to acquire Core Scientific about a year ago, offering $5.75 per share at the time; a bid that was rejected for undervaluing the business. Core Scientific shares now trade at more than double that earlier offer, giving the company a market capitalization of roughly $3.7 billion.
Core Scientific operates one of the largest high-powered digital infrastructure platforms in North America focused on bitcoin mining and hosting services. The company has seen growing interest amid a shortage of data center space and power capacity as demand from AI-related workloads continues to rise. It also maintains a significant 12-year hosting partnership with CoreWeave, delivering large-scale capacity for AI computing operations. 
CoreWeave, which went public in March and is valued at approximately $75 billion, specializes in cloud infrastructure for AI workloads. It serves major clients like Microsoft, its largest customer and acts as a middle layer offering access to Nvidia GPUs for firms such as Meta and IBM.
While Core Scientific shares rose on the takeover speculation, CoreWeave's stock slipped slightly reflecting typical market reactions in acquisition scenarios where the buyer faces potential integration or financing challenges.
Price Action: Core scientific shares were up 24% at $15.25 and Coreweave shares were down 1.13% at $157.80 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">Trump&#8217;s Fed Chairman Shortlist Is In: What Investors Need To Know</a></li>
</ul>
Image Via Shutterstock.

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

Core Scientific Stock Surges On Acquisition Reports With CoreWeave

BMO Capital analyst Ari Klein downgrades Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) from Outperform to Market Perform and lowers the price target from $1045 to $850.

Downgrades

EQIX

BMO Capital Downgrades Equinix to Market Perform, Lowers Price Target to $850

Wall Street entered full rally mode on Thursday, with the Nasdaq 100 extending its record-setting climb and the S&amp;P 500 approaching its February peak, as easing geopolitical fears and renewed hopes for a dovish Federal <a href="https://www.benzinga.com/topic/federal-reserve">Reserve lifted investor sentiment.</a>
By midday in New York, the S&amp;P 500 was up 0.7% to 6,136, just nine points shy of its all-time high of 6,145. The Nasdaq 100 rose another 0.7% to 22,400, marking yet another intraday record.
Meanwhile, small caps surged, with the Russell 2000 jumping 1%, outperforming the broader market.
On the macro front, the first-quarter GDP was revised downward to -0.5% from the previous -0.2% figure, primarily due to a widening goods trade deficit linked to weaker exports. Yet, other data released Thursday painted a more positive picture.
Factory orders in May soared by 16.4% month-over-month to $343.6 billion, marking the biggest increase since July 2014. That followed a revised 6.6% drop in April and smashed market expectations of an 8.5% gain. Weekly jobless claims fell by 10,000 to 236,000 in the week ending June 21, while economists had forecast no change — another sign of labor market resilience.
Currency markets added fuel to the equity rally. The U.S. dollar index fell to 97, its lowest level since February 2022, as traders increasingly bet that the next Fed chair nominee — with a <a href="https://www.benzinga.com/author/piero-cingari">shortlist reportedly down to four or five names</a> — will favor a dovish stance, potentially setting the stage for deeper rate cuts in 2026.
All S&amp;P 500 sectors traded in the green, except real estate. Energy stocks outperformed, rebounding after sharp down days as crude oil prices rose 2% to $66 per barrel.
Other commodities — especially metals — also rose, fueled by dollar weakness. Silver rose 1.2%, while palladium and <a href="https://www.benzinga.com/markets/commodities/25/06/46120819/platinum-miners-forecasts-stocks">platinum</a> spiked 6.1% and 4.3%, respectively. Copper rose 2.8% hitting a three-month high, while gold held steady at $3,330 per ounce.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was unchanged at $107,220. 
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>% Chg</td>
</tr>
<tr>
<td>• Russell 2000</td>
<td>2,158.05</td>
<td>+1.0%</td>
</tr>
<tr>
<td>• Dow Jones</td>
<td>43,355.44</td>
<td>+0.9%</td>
</tr>
<tr>
<td>• Nasdaq 100</td>
<td>22,403.44</td>
<td>+0.7%</td>
</tr>
<tr>
<td>• S&amp;P 500</td>
<td>6,136.45</td>
<td>+0.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.66% to $563.41.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.8% to $433.26.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;soared 0.7% to $544.72.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1% to $214.05.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.5%; the&nbsp;Real Estate&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged past $155 per share to hit record highs, becoming the world's most valuable company at $3.8 trillion.</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) slipped 1.1%, even after delivering <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46121658/micron-impresses-wall-street-with-strong-q3-earnings-continued-strength-in-ai-data-center">stronger-than-expected quarterly earnings</a>.</li>
<li>Other stocks reacting to earnings included Acuity Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>), up 7.1%; McCormick Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>), up 5.2% and Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), up 0.8%.</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) jumped 8%, lifted by rising metal prices, with industry peers Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>), and Alcoa Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) all rallying between 7% and 8%.</li>
<li>Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) sank 8% after unveiling a long-term growth outlook that underwhelmed investors.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) will report earnings after the close. </li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/46120819/platinum-miners-forecasts-stocks">Platinum&#8217;s Biggest Rally In 40 Years: These 6 Mining Stocks Could Be Top Gainers </a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Large Cap

Broad U.S. Equity ETFs

Commodities

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

NVDA

SCCO

XLRE

Stocks Rally To New Highs, Dollar Tumbles To 40-Month Lows: What's Driving Markets Thursday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Financials sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/25/25</td>
<td>$90.00</td>
<td>$50.5K</td>
<td>174</td>
<td>62.4K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$380.00</td>
<td>$91.5K</td>
<td>3.6K</td>
<td>6.4K</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$52.7K</td>
<td>21.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$90.00</td>
<td>$32.6K</td>
<td>2.7K</td>
<td>880</td>
</tr>
<tr>
<td>XYZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$70.00</td>
<td>$99.7K</td>
<td>3.2K</td>
<td>349</td>
</tr>
<tr>
<td>GS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$685.00</td>
<td>$44.8K</td>
<td>153</td>
<td>174</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$90.00</td>
<td>$26.6K</td>
<td>152</td>
<td>131</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$145.00</td>
<td>$47.7K</td>
<td>317</td>
<td>69</td>
</tr>
<tr>
<td>V</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$325.00</td>
<td>$231.8K</td>
<td>45</td>
<td>51</td>
</tr>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$42.00</td>
<td>$35.2K</td>
<td>35</td>
<td>42</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), we observe a call option sweep with bullish sentiment. It expires in 29 day(s) on July 25, 2025. Parties traded 500 contract(s) at a $90.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $101.0 per contract. There were 174 open contracts at this strike prior to today, and today 62481 contract(s) were bought and sold. 
• Regarding COIN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), we observe a call option trade with bullish sentiment. It expires in 7 day(s) on July 3, 2025. Parties traded 80 contract(s) at a $380.00 strike. The total cost received by the writing party (or parties) was $91.5K, with a price of $1144.0 per contract. There were 3601 open contracts at this strike prior to today, and today 6447 contract(s) were bought and sold. 
• For SOFI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), we notice a call option sweep that happens to be bullish, expiring in 568 day(s) on January 15, 2027. This event was a transfer of 197 contract(s) at a $25.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $52.7K, with a price of $268.0 per contract. There were 21522 open contracts at this strike prior to today, and today 1245 contract(s) were bought and sold. 
• Regarding HOOD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), we observe a call option sweep with bullish sentiment. It expires in 113 day(s) on October 17, 2025. Parties traded 31 contract(s) at a $90.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $1053.0 per contract. There were 2728 open contracts at this strike prior to today, and today 880 contract(s) were bought and sold. 
• For XYZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), we notice a call option sweep that happens to be bearish, expiring in 204 day(s) on January 16, 2026. This event was a transfer of 134 contract(s) at a $70.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $99.7K, with a price of $744.0 per contract. There were 3286 open contracts at this strike prior to today, and today 349 contract(s) were bought and sold. 
• For GS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on July 18, 2025. This event was a transfer of 20 contract(s) at a $685.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $44.8K, with a price of $2240.0 per contract. There were 153 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• For AFRM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), we notice a call option trade that happens to be bullish, expiring in 357 day(s) on June 18, 2026. This event was a transfer of 25 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $1065.0 per contract. There were 152 open contracts at this strike prior to today, and today 131 contract(s) were bought and sold. 
• For MS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), we notice a call option trade that happens to be bearish, expiring in 357 day(s) on June 18, 2026. This event was a transfer of 35 contract(s) at a $145.00 strike. The total cost received by the writing party (or parties) was $47.7K, with a price of $1365.0 per contract. There were 317 open contracts at this strike prior to today, and today 69 contract(s) were bought and sold. 
• For V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), we notice a call option sweep that happens to be bearish, expiring in 540 day(s) on December 18, 2026. This event was a transfer of 39 contract(s) at a $325.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $231.8K, with a price of $5945.0 per contract. There were 45 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
• Regarding LMND (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>), we observe a call option trade with bullish sentiment. It expires in 267 day(s) on March 20, 2026. Parties traded 30 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $1175.0 per contract. There were 35 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AFRM

COIN

HOOD

LMND

SOFI

10 Financials Stocks Whale Activity In Today's Session

<a href="https://www.youtube.com/watch?v=NKl2dpLylK0">https://www.youtube.com/watch?v=NKl2dpLylK0</a>

White House Says No Imminent Plans For Refilling Strategic Petroleum Reserve

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$330.00</td>
<td>$35.3K</td>
<td>18.2K</td>
<td>93.8K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$215.00</td>
<td>$43.8K</td>
<td>31.2K</td>
<td>50.2K</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$55.00</td>
<td>$96.6K</td>
<td>12.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/03/25</td>
<td>$61.00</td>
<td>$31.5K</td>
<td>3.0K</td>
<td>2.1K</td>
</tr>
<tr>
<td>HSAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$20.00</td>
<td>$29.9K</td>
<td>1.2K</td>
<td>965</td>
</tr>
<tr>
<td>EAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$130.00</td>
<td>$90.1K</td>
<td>3.5K</td>
<td>707</td>
</tr>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$27.00</td>
<td>$182.5K</td>
<td>465</td>
<td>607</td>
</tr>
<tr>
<td>LULU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$200.00</td>
<td>$50.7K</td>
<td>212</td>
<td>81</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$140.00</td>
<td>$37.7K</td>
<td>9</td>
<td>55</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2800.00</td>
<td>$940.5K</td>
<td>128</td>
<td>45</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on June 27, 2025. Parties traded 101 contract(s) at a $330.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $35.3K, with a price of $350.0 per contract. There were 18260 open contracts at this strike prior to today, and today 93841 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a call option trade with bearish sentiment. It expires in 1 day(s) on June 27, 2025. Parties traded 200 contract(s) at a $215.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 31250 open contracts at this strike prior to today, and today 50224 contract(s) were bought and sold. 
• Regarding CMG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), we observe a call option sweep with bullish sentiment. It expires in 7 day(s) on July 3, 2025. Parties traded 2597 contract(s) at a $55.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $96.6K, with a price of $37.0 per contract. There were 12103 open contracts at this strike prior to today, and today 2949 contract(s) were bought and sold. 
• Regarding NKE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on July 3, 2025. Parties traded 151 contract(s) at a $61.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.5K, with a price of $209.0 per contract. There were 3057 open contracts at this strike prior to today, and today 2187 contract(s) were bought and sold. 
• Regarding HSAI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>), we observe a call option sweep with neutral sentiment. It expires in 22 day(s) on July 18, 2025. Parties traded 100 contract(s) at a $20.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $29.9K, with a price of $299.0 per contract. There were 1224 open contracts at this strike prior to today, and today 965 contract(s) were bought and sold. 
• Regarding EAT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on January 16, 2026. Parties traded 15 contract(s) at a $130.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $90.1K, with a price of $6010.0 per contract. There were 3558 open contracts at this strike prior to today, and today 707 contract(s) were bought and sold. 
• Regarding LI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), we observe a put option sweep with bullish sentiment. It expires in 267 day(s) on March 20, 2026. Parties traded 500 contract(s) at a $27.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $182.5K, with a price of $365.0 per contract. There were 465 open contracts at this strike prior to today, and today 607 contract(s) were bought and sold. 
• For LULU (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>), we notice a call option trade that happens to be neutral, expiring in 204 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $50.7K, with a price of $5075.0 per contract. There were 212 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• For BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we notice a call option sweep that happens to be neutral, expiring in 568 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $140.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $37.7K, with a price of $1500.0 per contract. There were 9 open contracts at this strike prior to today, and today 55 contract(s) were bought and sold. 
• For MELI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), we notice a call option trade that happens to be bullish, expiring in 204 day(s) on January 16, 2026. This event was a transfer of 45 contract(s) at a $2800.00 strike. The total cost received by the writing party (or parties) was $940.5K, with a price of $20900.0 per contract. There were 128 open contracts at this strike prior to today, and today 45 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

BABA

HSAI

LULU

MELI

TSLA

10 Consumer Discretionary Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Information Technology sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$155.00</td>
<td>$104.4K</td>
<td>109.7K</td>
<td>244.6K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$15.00</td>
<td>$76.6K</td>
<td>22.1K</td>
<td>16.3K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$13.00</td>
<td>$157.9K</td>
<td>18.6K</td>
<td>9.5K</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$75.00</td>
<td>$28.2K</td>
<td>14.1K</td>
<td>8.3K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$23.00</td>
<td>$106.5K</td>
<td>17.5K</td>
<td>5.7K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$155.00</td>
<td>$83.3K</td>
<td>16.1K</td>
<td>3.1K</td>
</tr>
<tr>
<td>CRCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$200.00</td>
<td>$63.6K</td>
<td>2.6K</td>
<td>2.1K</td>
</tr>
<tr>
<td>QUBT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$17.00</td>
<td>$41.3K</td>
<td>661</td>
<td>975</td>
</tr>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$270.00</td>
<td>$30.6K</td>
<td>566</td>
<td>974</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$230.00</td>
<td>$101.8K</td>
<td>8.2K</td>
<td>706</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on June 27, 2025. This event was a transfer of 567 contract(s) at a $155.00 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $104.4K, with a price of $185.0 per contract. There were 109745 open contracts at this strike prior to today, and today 244656 contract(s) were bought and sold. 
• For CORZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), we notice a call option trade that happens to be bullish, expiring in 50 day(s) on August 15, 2025. This event was a transfer of 428 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $76.6K, with a price of $179.0 per contract. There were 22190 open contracts at this strike prior to today, and today 16304 contract(s) were bought and sold. 
• For IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>), we notice a call option sweep that happens to be bearish, expiring in 22 day(s) on July 18, 2025. This event was a transfer of 1500 contract(s) at a $13.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $157.9K, with a price of $106.0 per contract. There were 18664 open contracts at this strike prior to today, and today 9557 contract(s) were bought and sold. 
• Regarding MRVL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), we observe a call option sweep with bullish sentiment. It expires in 1 day(s) on June 27, 2025. Parties traded 57 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $495.0 per contract. There were 14123 open contracts at this strike prior to today, and today 8316 contract(s) were bought and sold. 
• Regarding INTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), we observe a call option sweep with bullish sentiment. It expires in 7 day(s) on July 3, 2025. Parties traded 3791 contract(s) at a $23.00 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $28.0 per contract. There were 17553 open contracts at this strike prior to today, and today 5709 contract(s) were bought and sold. 
• Regarding AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), we observe a call option sweep with bearish sentiment. It expires in 22 day(s) on July 18, 2025. Parties traded 391 contract(s) at a $155.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $83.3K, with a price of $213.0 per contract. There were 16194 open contracts at this strike prior to today, and today 3159 contract(s) were bought and sold. 
• For CRCL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on June 27, 2025. This event was a transfer of 30 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $63.6K, with a price of $2120.0 per contract. There were 2691 open contracts at this strike prior to today, and today 2148 contract(s) were bought and sold. 
• Regarding QUBT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on July 3, 2025. Parties traded 516 contract(s) at a $17.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $41.3K, with a price of $80.0 per contract. There were 661 open contracts at this strike prior to today, and today 975 contract(s) were bought and sold. 
• For AVGO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), we notice a put option sweep that happens to be bullish, expiring in 1 day(s) on June 27, 2025. This event was a transfer of 120 contract(s) at a $270.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $30.6K, with a price of $255.0 per contract. There were 566 open contracts at this strike prior to today, and today 974 contract(s) were bought and sold. 
• Regarding AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we observe a call option trade with bearish sentiment. It expires in 568 day(s) on January 15, 2027. Parties traded 51 contract(s) at a $230.00 strike. The total cost received by the writing party (or parties) was $101.8K, with a price of $1998.0 per contract. There were 8290 open contracts at this strike prior to today, and today 706 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

AVGO

CRCL

INTC

MRVL

QUBT

10 Information Technology Stocks Whale Activity In Today's Session

BMO Capital analyst Brian Quast downgrades Ascot Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AOT#TSX">AOT</a>) from Outperform to Market Perform.

TSX:AOT

BMO Capital Downgrades Ascot Resources to Market Perform

<a href="https://techcrunch.com/2025/06/26/rivian-cuts-dozens-on-manufacturing-team-ahead-of-r2-launch/">https://techcrunch.com/2025/06/26/rivian-cuts-dozens-on-manufacturing-team-ahead-of-r2-launch/</a>

RIVN

'Rivian cuts dozens on manufacturing team ahead of R2 launch'- Techcrunch

Susquehanna analyst Mehdi Hosseini maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Positive and raises the price target from $150 to $160.

Susquehanna Maintains Positive on Micron Technology, Raises Price Target to $160

Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is reportedly navigating heightened union tensions as Workers United launches a bold initiative encouraging labor organizers<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46053495/starbucks-green-apron-expansion-to-boost-service-but-squeeze-earnings-through-2027" rel="noreferrer noopener"> to apply for barista roles</a>.
The union&#8217;s move coincides with Starbucks&#8217; plans to bolster store staffing, potentially turning the company&#8217;s hiring spree into an unexpected organizing opportunity, Financial Times <a target="_blank" href="https://www.ft.com/content/89218b42-630e-4e8e-9720-b6b680c2022e" rel="noreferrer noopener">reports</a>.
Through a public campaign on social media, Workers United is recruiting &#8220;salts&#8221;—activists who seek employment with the aim of organizing from within.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/46066854/starbucks-denies-full-china-exit-amid-stake-sale-talks-as-market-share-slips-to-14" rel="noreferrer noopener">Starbucks Denies Full China Exit Amid Stake Sale Talks As Market Share Slips To 14%</a>
The initiative comes as the union has successfully won elections at 600 of Starbucks&#8217; more than 10,300 U.S. company-operated locations,
Starbucks executives recently acknowledged that prior staffing cuts weakened customer service. They subsequently announced a plan to expand headcount starting in August.
Last month, the union posted a call for applicants to join a new program that would assist them in landing jobs and organizing efforts from inside the cafés.
This open recruitment for salting reflects a strategic escalation and comes amid ongoing—but tense—contract negotiations with Starbucks. Walkouts over a new dress code last month underscored the strained relationship.
Starbucks criticized the union&#8217;s recruitment campaign, urging it to redirect energy toward finalizing a contract.
Sara Kelly, Starbucsk Chief Partner Officer, noted that more than 30 tentative agreements had been reached. She also warned against using resources to insert outside organizers, Financial Times adds.
Cornell labor expert Kate Bronfenbrenner explained that publicizing salting efforts signals sustained union pressure and intent to continue organizing efforts regardless of company resistance.
Meanwhile, Starbucks is denying reports it is considering a full exit from China. A spokesperson told Reuters the company isn't pursuing a full sale.
The Seattle-based company reportedly initiated a formal sale process in May, <a href="https://www.benzinga.com/markets/equities/25/06/46066854/starbucks-denies-full-china-exit-amid-stake-sale-talks-as-market-share-slips-to-14">with Goldman Sachs advising</a>.
Price Action: SBUX shares are trading lower by 0.48% to $90.62 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Image: Shutterstock

SBUX

Union 'Salts' Stir The Pot As Starbucks Ramps Up Hiring

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is approaching a pivotal support zone that could define its trend for <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">the remainder of the cycle</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1598</td>
<td>&nbsp;$23.9 billion</td>
<td>-5.6%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001122</td>
<td>&nbsp;$6.6 billion</td>
<td>-2.4%&nbsp;</td>
</tr>
<tr>
<td>Pepe</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.059214</td>
<td>&nbsp;$3.9 billion</td>
<td>-10.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Kevin has <a href="https://x.com/Kev_Capital_TA/status/1938218851134489002">flagged</a> the $0.143–$0.127 range as the make-or-break level for Dogecoin. 
This zone aligns with a cluster of technical supports: the 200-week SMA/EMA, a long-term downtrend support line, and a historically key level on Dogecoin's weekly RSI.
Kevin notes that since DOGE broke out of its 1.5-year bear market in 2022, each revisit to this RSI support zone has marked a macro higher low, followed by higher highs. 
If this zone fails, it will break that structure and could mark the beginning of a longer-term bearish phase. 
If it holds, Kevin sees a strong risk-reward setup with upside continuation likely, especially if Bitcoin dominance remains high.
Trader Tardigrade drew comparisons to DOGE's previous cycle moves—$0.0003 to $0.0026 to $0.009—and suggests the current cycle could mirror that trajectory, potentially leading to jumps from $0.42 to $1.46 to $4.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> jumped from $0.0003 to $0.0026 to $0.009 in the last cycle &#x1f525; In this cycle, <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> could see similar jumps, from $0.42 to $1.46 to $4 &#x1f680;<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a>/M1 <a href="https://t.co/k6kbCrqdVW">pic.twitter.com/k6kbCrqdVW</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1938236825728127080?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Bitinfocharts shows a rise in wallet accumulation: wallets holding 10 million–100 million DOGE increased from 747 (as of May 25) to 783 (June 25) while wallets with 1 million–10 million DOGE rose from 4,204 to 4,228.
Coinglass data shows DOGE derivatives open interest increased 2.7% to $.8 billion, while volume expanded 11.2% to $3 billion. Liquidations in the past 24 hours stood at $4.09 million with long liquidations at $2.99 million.
Community News: Bitwise Asset Management has filed updated <a href="https://www.sec.gov/Archives/edgar/data/2053791/000121390025058120/ea0246815-s1a1_bitwise.htm">S-1</a> forms with the SEC, including a Bitwise Dogecoin ETF, a move that would provide exposure to DOGE without requiring direct token ownership.
Dogecoin core contributor Mishaboar <a href="https://x.com/mishaboar/status/1936838567445102769">voiced</a> criticism toward major influencers in the DOGE space. 
He claims many who previously amplified Elon Musk's pro-Trump messages have begun deleting posts and walking back their public stance. 
Mishaboar slammed this behaviour as cowardly, warning that such influence, even when retracted, has real impact.
"These influencers built their platforms on Dogecoin's back, and now they're using it to amplify misguided political and billionaire-driven narratives," he said.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46102135/bitcoin-ethereum-xrp-holders-sitting-on-profits-while-dogecoin-trails-report">Bitcoin, Ethereum, XRP Holders Sitting On Profits, While Dogecoin Trails: Report</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Dogecoin ETF Nears But DOGE Down 5% In 7 Days: Bear Market Incoming?

Susquehanna analyst James Friedman maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Positive and raises the price target from $2840 to $2975.

Susquehanna Maintains Positive on MercadoLibre, Raises Price Target to $2975

Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), a biotechnology company focused on developing treatments for rare muscle disorders, recently unveiled promising results from its <a href="https://www.benzinga.com/general/health-care">sevasemten program</a> for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). 
Both are progressive genetic disorders characterized by muscle weakness and degeneration, with DMD typically being more severe and having an earlier onset than BMD.
On Thursday, the company announced data from MESA. This open-label extension trial provides continued access to sevasemten to participants with Becker who were previously enrolled in ARCH or completed CANYON, GRAND CANYON, or DUNE.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44610702/edgewise-therapeutics-sees-meaningful-hcm-treatment-gains-with-edg-7500-in-phase-2-study" rel="noreferrer noopener">Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study</a>
As of the&nbsp;March 2025&nbsp;data cut, 99% of eligible participants (n=85) are enrolled in MESA. The MESA data demonstrated sustained disease stabilization.
CANYON participants who rolled over to MESA showed increased North Star Ambulatory Assessment (NSAA) scores over 18 months (0.8 point improvement from baseline), with a trend toward improvement in placebo participants switching to sevasemten (0.2 point improvement since <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46110778/edgewise-therapeutics-reports-positive-results-on-sevasemten-program-for-becker-and-duchenne-muscu" rel="noreferrer noopener">initiation of sevasemten)</a>.
NSAA measures functional motor abilities in ambulant (who can walk) children with Duchenne. During the 18 months of sevasemten treatment, participants&#8217; NSAA scores continued to diverge relative to the expected functional declines seen in multiple Becker natural history studies.
Further, NSAA scores for ARCH participants who rolled over to MESA remained stable after three years of treatment. Sevasemten demonstrates a favorable safety profile after up to three years of treatment.&nbsp;
Edgewise recently completed a Type C meeting with the U.S. Food and Drug Administration (FDA).
While the FDA deemed the CANYON data insufficient for accelerated approval, the Agency reiterated that NSAA is a clinically meaningful endpoint for traditional approval.
Accelerated approval is an FDA pathway that allows for earlier approval of drugs for serious conditions that fill an unmet medical need, based on a surrogate endpoint (a measure that is reasonably likely to predict clinical benefit). 
However, it requires confirmatory trials post-approval. Traditional approval, on the other hand, typically requires more extensive clinical trial data demonstrating direct clinical benefit.
GRAND CANYON is highly powered to show a statistically significant difference in NSAA versus placebo over 18 months and is on track for topline data in the fourth quarter of 2026.&nbsp;
The company also announced topline data from its Phase 2 Duchenne trials, LYNX and FOX.
The goals were to explore a range of doses to assess safety and identify a potentially beneficial dose for Phase 3. Across both studies, sevasemten was well-tolerated at target doses.
LYNX is an ongoing Phase 2 trial to evaluate the effect of sevasemten on safety, biomarkers of muscle damage, and function in four- to nine-year-old participants with Duchenne treated with sevasemten.
The company identified a dose of 10 mg to evaluate in Phase 3.&nbsp;
Similar to the LYNX design, FOX is an ongoing Phase 2 trial to evaluate the effect of sevasemten on safety, biomarkers of muscle damage, and function in six- to 14-year-old participants with Duchenne who have been previously treated with gene therapy.
The company plans to meet with the FDA in the fourth quarter of 2025 to discuss a Phase 3 design, including input on the patient population and endpoints, with plans to initiate the pivotal study in 2026.
Price Action: EWTX stock is down 11.6% at $12.68 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46117699/poet-technologies-stock-surges-on-ai-award-manufacturing-momentum" target="_blank" rel="noreferrer noopener">POET Technologies Stock Surges On AI Award, Manufacturing Momentum</a></li>
</ul>
Photo via Shutterstock

EWTX

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall

<a href="https://www.bloomberg.com/news/articles/2025-06-26/no-decision-imminent-on-next-fed-chair-white-house-says">https://www.bloomberg.com/news/articles/2025-06-26/no-decision-imminent-on-next-fed-chair-white-house-says</a>

'Trump Decision on Next Fed Chair Not Imminent, White House Says'- Bloomberg

Stifel analyst David Grossman maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Hold and lowers the price target from $156 to $152.

PAYX

Stifel Maintains Hold on Paychex, Lowers Price Target to $152

<a href="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent" title="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent">https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent</a>

'Meta in Talks to Buy AI Voice Startup PlayAI in Push for Talent' - Bloomberg News

<ul>
<li>Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service</li>
<li>Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.
He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board.
At the AGM, where 80.4% of QIAGEN's issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million.
Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science &amp; Technology and Human Resources &amp; Compensation Committees.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner.
The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski.
Shareholders also approved the initiation of QIAGEN's first-ever annual cash dividend - a milestone that reflects QIAGEN's strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases.
The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025.
In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN's commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth.

Dividends

Buybacks

Management

QGEN

QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Novavax

ARS Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Verve Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

JP Morgan

RBC Capital

Baird

Morgan Stanley

HC Wainwright & Co.

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) 주식은 지난주 65.57% 급등했다.
2. 스칼러 락 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) 주식은 경쟁사인 바이오헤이븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)의 척수성 근위축증에 대한 탈데프그로베프(taldefgrobep)가 <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3상 연구에 실패한 후</a> 주가는 49.61% 급등했다.
3. 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) 주식은 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)와 여러 임상 및 전임상 siRNA 프로그램에 대한 글로벌 라이선스 및 협력 계약을 체결한 후 42.40% 상승했다.
4. 아이리스 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) 주식은 회사가 1분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 38.99% 급등했다.
5. 힘스 앤 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주식은 대통령 당선인 도널드 트럼프가 마티 마카리(Marty Makary)를 식품의약국(FDA) 수장으로 지명할 계획을 발표한 후 33.42% 상승했다.
6. 사운드하운드 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) 주식은 33.38% 상승했다. 이 회사는 최근 <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">AEMA 그룹의 일부로 아피비아 쿠르타주</a>(Apivia Courtage)에 대화형 AI 에이전트인 아멜리아(Amelia)를 배포했다고 발표했다.
7. 조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) 주식은 토요타 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)가 이 회사에 5억 달러를 투자했다는 발표 후 31.62% 상승했다.
8. 어번 아웃피터스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) 주식은 회사가 3분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 30.43% 상승했다.
 
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%A1%9C%EC%BC%93%EB%9E%A9-%EB%B0%8F-%EB%AA%A8%EB%8D%94%EB%82%98%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B7%B8%EB%9E%A9-%EB%B0%8F-%EC%98%A4%ED%86%A0%EB%8D%B0%EC%8A%A4%ED%81%AC-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-11/" target="_blank" rel="noopener">레딧, 그랩 및 오토데스크 지난주 최악의 성과를 보인 11개 대형주 중 일부 (11월 25일-29일)</a></li>
</ul>
이미지 출처: Archer


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 어큐이티 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>)가 분기별 실적을 주당 $4.28, 매출 $10.2억 달러로 예상하고 있으며, 시장 개장 전에 실적을 발표할 것이라고 전했다. 어큐이티 브랜즈의 주식은 애프터 마켓에서 1.7% 상승하여 $279.94에 거래되었다.
2. 리포시트랙(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>)은 4분기 재무 실적이 예상보다 좋았으며 분기 배당금을 10% 인상했다고 발표했다. 리포시트랙의 주식은 애프터 마켓에서 4.6% 상승하여 $19.32에 거래되었다.
3. 애널리스트들은 맥코믹 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>)가 최근 분기 매출 $167만, 주당 67센트의 이익을 기록했다. 이 회사는 시장이 열리기 전에 실적을 발표할 예정이다. 맥코믹의 주가는 시간외 거래에서 0.4% 상승한 $82.60을 기록했다.
프리마켓 보도를 확인하시려면 <a href="https://www.benzinga.com/premarket/">여기</a>를 클릭하세요.
4. 바이오헤이븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)는 2억 5천만 달러 규모의 보통주 공모를 제안했다고 발표했다. 바이오헤이븐의 주식은 애프터 마켓에서 1.9% 하락하여 $49.00에 거래되었다.
5. 애널리스트들은 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)가 마감 후 분기 매출 $1,165만, 주당 52센트의 분기 이익을 게시할 예정이다. 나이키의 주가는 시간외 거래에서 0.1% 하락한 $88.31를 기록했다.
이것을 확인하세요:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">짐 크레이머가 선정한 중국 경기 부양책 열풍을 타고 갈 3개 주식</a></li>
</ul>
사진 제공: Shutterstock

스트럭처 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다.
What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#8220;비중확대(Overweight)&#8221; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.
스트럭처 테라퓨틱스는 GLP-1 체중 감량 시장을 겨냥해 고안된 경구용 알약인 &#8216;1290&#8217;이라는 약물 후보를 개발하고 있다. 이 약물은 잠재적으로 경쟁사보다 1~2년 앞서 시장에 출시될 수 있는 소분자 제제를 기반으로 한다.
이 약은 다른 경구용 체중 감량 약물 후보와 차별화되어 안전성에 큰 우려가 없는 환자에게 상당한 체중 감량 효과를 제공할 것으로 기대된다.
"우리는 전례 없이 큰 시장에서 구강 시장에서 GPCR의 시장 점유율이 시간이 지남에 따라 5%에 접근할 수 있다고 생각한다. 전체적으로 우리는 1290/스트럭처가 T2D/비만 시장에 참여하려는 대규모 바이오제약 회사들에게 매력적인 파트너십 기회가 될 수 있다고 생각한다"라고 JP모건이 말했다.
JP모건은 스트럭처 테라퓨틱스의 경구용 GLP-1 체중 감량 약물 후보가 2035년까지 10억 달러 이상의 최고 매출을 올릴 수 있을 것으로 믿고 있다. 이 회사는 2023년 2월에 상장되었다.
참조: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38910906/bitcoin-dogecoin-ethereum-retrace-on-profit-taking-by-retail-investors-analyst-predicts-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 도지코인, 이더리움은 소매 투자자들의 이익 실현에 하락</a>
Why It Matters: 비만 치료제 시장은 중요한 발전을 보이고 있다. 최근 로슈(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)은 이중 GLP-1/GIP 수용체 작용제 CT-388의 1b상 시험에서 유망한 결과를 발표하여 비만 치료 시장에서 <a href="https://www.benzinga.com/general/biotech/24/05/38878582/roche-to-ride-booming-obesity-treatment-market-with-newly-acquired-drug-candidate">상당한 잠재력</a>을 나타냈다.
또한 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 중국에서 당뇨병 치료제 티르제파티드(tirzepatide)에 대한 승인을 확보하여 중요한 아시아 시장에서 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와의 <a href="https://www.benzinga.com/general/biotech/24/05/38941485/eli-lilly-secures-china-nod-for-popular-weight-lossdiabetes-drug-tirzepatide">경쟁</a>이 치열해질 수 있는 발판을 마련했다.
앞서 바이오헤븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)은 체중 감량을 돕는 동시에 근육 손실을 예방할 수 있는 실험 약물인 탈데프그로벱 알파(taldefgrobep alfa)(BHVN-2000)를 통해 비만 치료제 시장에 대한 <a href="https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff">다른</a> 접근 방식을 강조했다.
다음 읽기: <a href="https://www.benzinga.com/tech/24/05/38919616/apples-groundbreaking-iphone-16-could-spark-another-stock-surge-building-on-an-800-growth-over-the-l?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, 6월 WWDC에서 아이폰 13 시리즈 공개 예고</a>
AI를 통해 생산된 이미지
<hr class="wp-block-separator has-alpha-channel-opacity" />
Benzinga Neuro의 기술, <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a> 편집
<hr class="wp-block-separator has-alpha-channel-opacity" />
GPT-4 기반의 Benzinga Neuro 콘텐츠 생성 시스템은 광벤짜 생태계의 네이티브 데이터, API 등을 활용하여 포괄적이고 시의적절한 이야기를 제공합니다. <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">더 알아보기</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />

Comments

Biohaven

뉴스

에 대한 최신 뉴스 Biohaven (NYSE:BHVN) 주식

일요일, 12월 01, 2024

화요일, 10월 01, 2024

수요일, 5월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌